「in vitroinvivo」の検索結果
158件：61～65件目を表示
-
econdary to age-related macular degeneration and the complement pathway as a therapeutic target. Retina. 2017;37(5):819-835. 2 Cheung, C.M.G., Chen, Y., Holz, F.G. et al. Geographic atrophy in Asia. G...
https://www.senju.co.jp/system/files/content_news/2025-11/JPN_20251127.pdf -
Production | About Senju | SENJU Pharmaceutical
Trusted pharmaceutical products are created using the latest and best equipment in the environment with rich humanity. As ophthalmic solutions are required to meet the same quality standards as inject...
http://www.senju.co.jp/english/about/production.html -
オロパタジン点眼液0.1％「センジュ」
感作モルモットの抗原誘発によ る眼瞼と眼球結膜の充血及び膨疹を抑制 （ED50値：0.017%） し た12） 。 19. 有効成分に関する理化学的知見 一般名：オロパタジン塩酸塩 （Olopatadine Hydrochloride） 〔JAN〕 化学名： ｛11-[ （1 ） -3- （Dimethylamino） propylidene]-6, 11- dihydrodibenzo[b, e...
https://www.senju.co.jp/system/files/product_other_file/2023-10/olopatadine_202312_C3.pdf -
rmaceutical Co., Ltd. Mochida Pharmaceutical Co., Ltd. Senju has successfully completed Phase III clinical trials in Japan for the novel Dry Eye Disease treatment, SJP-0132 Senju Pharmaceutical Co., L...
https://www.senju.co.jp/system/files/content_news/2024-07/ENG_20240716.pdf -
nt: Senju Pharmaceutical Co., Ltd. Mochida Pharmaceutical Co., Ltd. Senju has Applied for Manufacturing and Marketing Approval in Japan for the novel Dry Eye Disease treatment, SJP-0132 Senju Pharmace...
https://www.senju.co.jp/system/files/content_news/2025-01/ENG_20250117.pdf